Acacia: Fishing for support

Acacia Pharma Ltd. is applying the reprofiling model to hospital-based supportive care with an initial focus on cancer, a market the company says has limited competition and a low cost of development relative to primary care.

"There are a lot of reasons that cancer supportive care is becoming more attractive," including an aging population and increases in conditions like diabetes that increase the risk of cancer, as well as new therapies coming to market that prolong the lives of patients with cancer and consequently extend the need for care, CEO Julian Gilbert told BioCentury. "We felt this was an area that was coming of age."...